Summarized by Masters of Longevity from PR Newswire.
This article previews a clinical-trial news piece about an off-the-shelf stem cell therapy for Parkinson’s, highlighting early-phase safety and trial enrollment milestones.
Key Takeaways
- Phase I single-arm trial of the allogeneic iPSC-derived product enrolled nine participants and met primary safety objectives.
- Post-transplant 18F-DOPA PET showed increased putaminal specific binding ratios consistent with graft survival and dopaminergic function.
- A multicenter randomized PROBE Phase II in China completed enrollment of all 30 participants and finished treatment group transplantation.
